Sandostatin LAR, the long-acting injectable form of octreotide, costs roughly $6,200 per monthly dose at its Medicare reimbursement price. That adds up to more than $74,000 a year for a single patient. The price reflects a combination of complex manufacturing, limited competition, and the realities of treating rare conditions where few alternatives exist.
What Sandostatin Treats and Why That Matters
Sandostatin is a synthetic version of a hormone your body naturally produces called somatostatin. It slows the release of other hormones and chemicals that drive tumor growth and uncomfortable symptoms like severe diarrhea, flushing, and wheezing. It’s primarily used for acromegaly (a condition caused by excess growth hormone) and neuroendocrine tumors, including carcinoid tumors and VIPomas.
These are rare conditions. Neuroendocrine tumors affect a small fraction of the population, which means the drug’s development costs get spread across a much smaller customer base than, say, a cholesterol medication taken by millions. Drugmakers routinely price rare-disease treatments higher to recoup research investments and maintain profitability on low-volume products. Sandostatin received orphan drug designation from the FDA in 1998 for treating VIPoma-related diarrhea, which granted Novartis seven years of market exclusivity for that specific use.
The Manufacturing Problem
The long-acting version of Sandostatin isn’t a simple pill or even a standard injection. It uses a specialized delivery system built on PLGA microspheres, tiny biodegradable particles that slowly release the drug over about four weeks after a single injection into the muscle. This is what allows patients to get one shot per month instead of multiple daily injections.
Making these microspheres consistently is genuinely difficult. The polymer used has a branched molecular structure with multiple sites where chemical reactions can occur, leading to wide variation in how the branches form. During production, the sugar molecule at the core of the polymer can undergo unwanted side reactions at high temperatures, altering its structure before it can do its job. These competing reactions make quality control a serious challenge. Even characterizing the final polymer fully, measuring not just its molecular weight but its actual branching structure, requires techniques that haven’t been fully standardized.
This complexity isn’t just an academic concern. It directly affects how long the drug took to reach market, how expensive the production facilities are to build and maintain, and how hard it is for other companies to replicate the product.
Why Generics Took So Long
For any generic version of Sandostatin LAR to win FDA approval, the manufacturer must prove its product is bioequivalent to the original. With a standard tablet, that’s relatively straightforward. With PLGA microspheres, it’s a much higher bar. The generic company has to demonstrate that its polymer is qualitatively the same as Novartis’s version, and researchers have noted that determining this “sameness” remains a challenge for both regulators and the generic drug industry.
The result: Sandostatin LAR went without generic competition for years. It wasn’t until October 2024 that Teva Pharmaceuticals launched the first and only generic version of Sandostatin LAR in the United States. Before that, Novartis had the market essentially to itself for the long-acting formulation. Even now, with just one generic competitor, pricing pressure is limited compared to drugs that have five or ten generic options.
Novartis’s Pricing Power
Sandostatin remains a significant revenue source for Novartis. The Sandostatin product group generated $1.213 billion in global net sales through early 2025, though that figure was down 5% from the prior year, likely reflecting the entry of Teva’s generic. For years before generic competition, Novartis had little market incentive to lower the price. The only real alternative, lanreotide (sold as Somatuline Depot), costs even more: approximately $7,600 per monthly dose compared to Sandostatin LAR’s roughly $6,200, based on Medicare average sales prices from 2020. When your only competitor is more expensive, there’s no downward pressure on your price.
What You Actually Pay
Sandostatin LAR is typically covered under Medicare Part B rather than Part D because it must be administered under the direct supervision of a physician. That means it’s billed as a medical service, not a pharmacy prescription. Under Part B, patients are generally responsible for 20% coinsurance after meeting their deductible, which on a $6,200 monthly drug still amounts to more than $1,200 per injection out of pocket before any supplemental coverage kicks in.
For privately insured patients, Novartis offers a co-pay program that can reduce your monthly cost to as little as $25, with Novartis covering up to $15,000 in co-pays per calendar year. This program is not available to anyone enrolled in Medicare, Medicaid, or other federal healthcare programs. Novartis also runs a separate patient assistance program through its foundation that provides the drug free of charge to eligible U.S. residents who have limited or no prescription coverage and meet income requirements.
Will Prices Drop Now?
Teva’s generic launch in late 2024 is the most significant development in Sandostatin pricing in decades. Historically, the first generic version of a specialty injectable doesn’t slash prices the way generics do for simple tablets. Initial discounts for complex generics tend to be modest, often 15% to 30% below the brand price, because the manufacturing barriers that made the generic hard to develop also limit how many competitors will enter the market.
Still, the trajectory is toward lower costs. If additional generic manufacturers clear the regulatory hurdles and enter the market, prices should fall further. For now, if you’re paying out of pocket or facing high coinsurance, asking your provider about the generic option or contacting Novartis’s assistance programs are the most immediate ways to reduce your costs.